The Clinical Status of Stem Cell Therapy for Ischemic Cardiomyopathy
Ischemic cardiomyopathy (ICM) is becoming a leading cause of morbidity and mortality in the whole world. Stem cell-based therapy is emerging as a promising option for treatment of ICM. Several stem cell types including cardiac-derived stem cells (CSCs), bone marrow-derived stem cells, mesenchymal st...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Stem Cells International |
| Online Access: | http://dx.doi.org/10.1155/2015/135023 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849473172245577728 |
|---|---|
| author | Xianyun Wang Jun Zhang Fan Zhang Jing Li Yaqi Li Zirui Tan Jie Hu Yixin Qi Quanhai Li Baoyong Yan |
| author_facet | Xianyun Wang Jun Zhang Fan Zhang Jing Li Yaqi Li Zirui Tan Jie Hu Yixin Qi Quanhai Li Baoyong Yan |
| author_sort | Xianyun Wang |
| collection | DOAJ |
| description | Ischemic cardiomyopathy (ICM) is becoming a leading cause of morbidity and mortality in the whole world. Stem cell-based therapy is emerging as a promising option for treatment of ICM. Several stem cell types including cardiac-derived stem cells (CSCs), bone marrow-derived stem cells, mesenchymal stem cells (MSCs), skeletal myoblasts (SMs), and CD34+ and CD 133+ stem cells have been applied in clinical researches. The clinical effect produced by stem cell administration in ICM mainly depends on the transdifferentiation and paracrine effect. One important issue is that low survival and residential rate of transferred stem cells in the infracted myocardium blocks the effective advances in cardiac improvement. Many other factors associated with the efficacy of cell replacement therapy for ICM mainly including the route of delivery, the type and number of stem cell infusion, the timing of injection, patient’s physical condition, the particular microenvironment onto which the cells are delivered, and clinical condition remain to be addressed. Here we provide an overview of the pros and cons of these transferred cells and discuss the current state of their therapeutic potential. We believe that stem cell translation will be an ideal option for patients following ischemic heart disease in the future. |
| format | Article |
| id | doaj-art-d85bcc554a4b48edb26c5d6496ac3e5e |
| institution | Kabale University |
| issn | 1687-966X 1687-9678 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Stem Cells International |
| spelling | doaj-art-d85bcc554a4b48edb26c5d6496ac3e5e2025-08-20T03:24:15ZengWileyStem Cells International1687-966X1687-96782015-01-01201510.1155/2015/135023135023The Clinical Status of Stem Cell Therapy for Ischemic CardiomyopathyXianyun Wang0Jun Zhang1Fan Zhang2Jing Li3Yaqi Li4Zirui Tan5Jie Hu6Yixin Qi7Quanhai Li8Baoyong Yan9Cell Therapy Laboratory, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, ChinaCell Therapy Laboratory, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, ChinaCell Therapy Laboratory, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, ChinaCell Therapy Laboratory, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, ChinaDepartment of Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, ChinaDepartment of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, ChinaSchool of Nursing, Hebei Medical University, Shijiazhuang, Hebei 050000, ChinaDepartment of General Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, ChinaCell Therapy Laboratory, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, ChinaCell Therapy Laboratory, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, ChinaIschemic cardiomyopathy (ICM) is becoming a leading cause of morbidity and mortality in the whole world. Stem cell-based therapy is emerging as a promising option for treatment of ICM. Several stem cell types including cardiac-derived stem cells (CSCs), bone marrow-derived stem cells, mesenchymal stem cells (MSCs), skeletal myoblasts (SMs), and CD34+ and CD 133+ stem cells have been applied in clinical researches. The clinical effect produced by stem cell administration in ICM mainly depends on the transdifferentiation and paracrine effect. One important issue is that low survival and residential rate of transferred stem cells in the infracted myocardium blocks the effective advances in cardiac improvement. Many other factors associated with the efficacy of cell replacement therapy for ICM mainly including the route of delivery, the type and number of stem cell infusion, the timing of injection, patient’s physical condition, the particular microenvironment onto which the cells are delivered, and clinical condition remain to be addressed. Here we provide an overview of the pros and cons of these transferred cells and discuss the current state of their therapeutic potential. We believe that stem cell translation will be an ideal option for patients following ischemic heart disease in the future.http://dx.doi.org/10.1155/2015/135023 |
| spellingShingle | Xianyun Wang Jun Zhang Fan Zhang Jing Li Yaqi Li Zirui Tan Jie Hu Yixin Qi Quanhai Li Baoyong Yan The Clinical Status of Stem Cell Therapy for Ischemic Cardiomyopathy Stem Cells International |
| title | The Clinical Status of Stem Cell Therapy for Ischemic Cardiomyopathy |
| title_full | The Clinical Status of Stem Cell Therapy for Ischemic Cardiomyopathy |
| title_fullStr | The Clinical Status of Stem Cell Therapy for Ischemic Cardiomyopathy |
| title_full_unstemmed | The Clinical Status of Stem Cell Therapy for Ischemic Cardiomyopathy |
| title_short | The Clinical Status of Stem Cell Therapy for Ischemic Cardiomyopathy |
| title_sort | clinical status of stem cell therapy for ischemic cardiomyopathy |
| url | http://dx.doi.org/10.1155/2015/135023 |
| work_keys_str_mv | AT xianyunwang theclinicalstatusofstemcelltherapyforischemiccardiomyopathy AT junzhang theclinicalstatusofstemcelltherapyforischemiccardiomyopathy AT fanzhang theclinicalstatusofstemcelltherapyforischemiccardiomyopathy AT jingli theclinicalstatusofstemcelltherapyforischemiccardiomyopathy AT yaqili theclinicalstatusofstemcelltherapyforischemiccardiomyopathy AT ziruitan theclinicalstatusofstemcelltherapyforischemiccardiomyopathy AT jiehu theclinicalstatusofstemcelltherapyforischemiccardiomyopathy AT yixinqi theclinicalstatusofstemcelltherapyforischemiccardiomyopathy AT quanhaili theclinicalstatusofstemcelltherapyforischemiccardiomyopathy AT baoyongyan theclinicalstatusofstemcelltherapyforischemiccardiomyopathy AT xianyunwang clinicalstatusofstemcelltherapyforischemiccardiomyopathy AT junzhang clinicalstatusofstemcelltherapyforischemiccardiomyopathy AT fanzhang clinicalstatusofstemcelltherapyforischemiccardiomyopathy AT jingli clinicalstatusofstemcelltherapyforischemiccardiomyopathy AT yaqili clinicalstatusofstemcelltherapyforischemiccardiomyopathy AT ziruitan clinicalstatusofstemcelltherapyforischemiccardiomyopathy AT jiehu clinicalstatusofstemcelltherapyforischemiccardiomyopathy AT yixinqi clinicalstatusofstemcelltherapyforischemiccardiomyopathy AT quanhaili clinicalstatusofstemcelltherapyforischemiccardiomyopathy AT baoyongyan clinicalstatusofstemcelltherapyforischemiccardiomyopathy |